(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025
Ocular Therapeutix shares surged 28.1% to $16.11 on December 8, hitting a new 52-week high after the company announced plans to file an accelerated NDA for its retina drug AXPAXLI in wet AMD, based on a single Phase 3 trial. Trading volume spiked, and year-to-date gains reached about 44%. The company aims to submit the NDA after year-one SOL-1 trial data in Q1 2026.
